ArticleJournal of experimental & clinical cancer research : CR2021

Complement inhibitor CSMD1 modulates epidermal growth factor receptor oncogenic signaling and sensitizes breast cancer cells to chemotherapy.

Chrysostomi Gialeli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.